[Vaccines for the treatment of non-small cell lung cancer]
/in Dendritic Cells, International Publications, NSCLC /von 2019-03-20 / Rev Mal Respir 2019 Mar;36(3):415-425Recent Advances in Cancer Stem Cell-Targeted Immunotherapy
/in Dendritic Cells, International Publications, Newcastle Disease Virus /von 2019-03-05 / Cancers (Basel) 2019 Mar;11(3)Hypomethylating agent alters the immune microenvironment in acute myeloid leukaemia (AML) and enhances the immunogenicity of a dendritic cell/AML vaccine
/in Acute Leukemia, Dendritic Cells, International Publications /von 2019-03-03 / Br. J. Haematol. 2019 May;185(4):679-690Randomized phase II trial of patient-specific dendritic cell vaccines loaded with autologous tumor antigens versus autologous monocytes in patients with primary advanced ovarian cancer.
/in Dendritic Cells, International Publications, Ovarian Cancer /von 2019-03-01 / J Clin Oncol 37, 2019 (suppl 8; abstr TPS10)Biologics, Immunotherapy, and Future Directions in the Treatment of Advanced Cholangiocarcinoma
/in Dendritic Cells, Gallbladder Cancer, International Publications /von 2019-02-27 / Clin Colorectal Cancer 2019 Jun;18(2):81-90Maintenance of long remission in adult T-cell leukemia by Tax-targeted vaccine: A hope for disease-preventive therapy
/in Acute Leukemia, Dendritic Cells, International Publications, Malignant Lymphoma /von 2019-02-19 / Cancer Sci. 2019 Mar;110(3):849-857On the Other Side: Manipulating the Immune Checkpoint Landscape of Dendritic Cells to Enhance Cancer Immunotherapy
/in Checkpoint-Inhibitors, Dendritic Cells, International Publications /von 2019-02-06 / Front Oncol 2019;9:50The evolving clinical landscape for dendritic cell vaccines and cancer immunotherapy
/in Dendritic Cells, International Publications /von 2019-02-01 / Immunotherapy 2019 Feb;11(2):75-79Dendritic cell vaccination plus low-dose doxorubicin for the treatment of spontaneous canine hemangiosarcoma
/in Dendritic Cells, International Publications, Soft Tissue Sarcoma /von 2019-01-23 / Cancer Gene Ther. 2019 09;26(9-10):282-291IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de